Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Bertilimumab> ?p ?o. }
Showing items 1 to 38 of
38
with 100 items per page.
- Bertilimumab abstract "Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function.It was discovered by Cambridge Antibody Technology using their phage display technology. Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders.In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc. iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'.iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis.In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by Lonza, in its cGMP facilities in Slough, UK. Subsequently iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield.In June 2011, IMMUNE Pharmaceuticals (Herzliya, Israel) in-licensed Bertilimumab from iCo for non-ophthalmic indications. IMMUNE is initiating Phase II clinical trials of Bertilimumab in inflammatory bowel disease (ulcerative colitis & Crohn's disease) in 2012 and 2013.".
- Bertilimumab atcPrefix "none".
- Bertilimumab casNumber "375348-49-5".
- Bertilimumab wikiPageID "9124274".
- Bertilimumab wikiPageRevisionID "590759657".
- Bertilimumab atcPrefix "none".
- Bertilimumab casNumber "375348".
- Bertilimumab chemspiderid "NA".
- Bertilimumab hasPhotoCollection Bertilimumab.
- Bertilimumab mabType "mab".
- Bertilimumab source "u".
- Bertilimumab target CCL11.
- Bertilimumab type "mab".
- Bertilimumab verifiedfields "changed".
- Bertilimumab verifiedrevid "459958463".
- Bertilimumab subject Category:Experimental_medical_treatments.
- Bertilimumab type Abstraction100002137.
- Bertilimumab type Act100030358.
- Bertilimumab type Activity100407535.
- Bertilimumab type Care100654885.
- Bertilimumab type Event100029378.
- Bertilimumab type ExperimentalMedicalTreatments.
- Bertilimumab type PsychologicalFeature100023100.
- Bertilimumab type Treatment100658082.
- Bertilimumab type Work100575741.
- Bertilimumab type YagoPermanentlyLocatedEntity.
- Bertilimumab type Drug.
- Bertilimumab type DrugProduct.
- Bertilimumab type FunctionalSubstance.
- Bertilimumab comment "Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function.It was discovered by Cambridge Antibody Technology using their phage display technology. Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders.In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc. iCo Therapeutics Inc.".
- Bertilimumab label "Bertilimumab".
- Bertilimumab label "برتيليموماب".
- Bertilimumab sameAs m.027yjvp.
- Bertilimumab sameAs Q4895713.
- Bertilimumab sameAs Q4895713.
- Bertilimumab sameAs Bertilimumab.
- Bertilimumab wasDerivedFrom Bertilimumab?oldid=590759657.
- Bertilimumab isPrimaryTopicOf Bertilimumab.